Cargando…

Efficacy and Renal Safety of Prophylactic Tenofovir Alafenamide for HBV-Infected Cancer Patients Undergoing Chemotherapy

There are no data comparing the efficacy and safety of prophylactic entecavir (ETV), tenofovir disoproxil fumarate (TDF) and tenofovir alafenamide (TAF) for HBV-infected cancer patients undergoing chemotherapy. This study aimed to compare the efficacy and renal safety of ETV, TDF and TAF in this set...

Descripción completa

Detalles Bibliográficos
Autores principales:	Lee, I-Cheng, Lan, Keng-Hsin, Su, Chien-Wei, Li, Chung-Pin, Chao, Yee, Lin, Han-Chieh, Hou, Ming-Chih, Huang, Yi-Hsiang
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2022
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9569539/ https://www.ncbi.nlm.nih.gov/pubmed/36232631 http://dx.doi.org/10.3390/ijms231911335

Ejemplares similares

3-year Treatment of Tenofovir Alafenamide vs. Tenofovir Disoproxil Fumarate for Chronic HBV Infection in China
por: Hou, Jinlin, et al.
Publicado: (2021)

Antiviral kinetics of tenofovir alafenamide and tenofovir disoproxil fumarate over 24 weeks in women of childbearing potential with chronic HBV
por: Pan, Calvin Q., et al.
Publicado: (2021)

Tenofovir Alafenamide in Multimorbid HIV-Infected Patients With Prior Tenofovir-Associated Renal Toxicity
por: Walti, Laura N, et al.
Publicado: (2018)

Exosomal lncRNA HOTTIP Mediates Antiviral Effect of Tenofovir Alafenamide (TAF) on HBV Infection
por: Liu, Qing-Min, et al.
Publicado: (2021)

Development of a Transdermal Delivery System for Tenofovir Alafenamide, a Prodrug of Tenofovir with Potent Antiviral Activity Against HIV and HBV
por: Puri, Ashana, et al.
Publicado: (2019)

Coformulated bictegravir, emtricitabine, tenofovir alafenamide after initial treatment with bictegravir or dolutegravir and emtricitabine/tenofovir alafenamide
por: Sax, Paul E., et al.
Publicado: (2018)

Impact of switching to tenofovir alafenamide on weight gain as compared to maintaining a non-tenofovir alafenamide containing regimen
por: Darnell, Julia, et al.
Publicado: (2021)

Tenofovir Alafenamide Rescues Renal Tubules in Patients with Chronic Hepatitis B
por: Sano, Tomoya, et al.
Publicado: (2021)

A Review and Clinical Understanding of Tenofovir: Tenofovir Disoproxil Fumarate versus Tenofovir Alafenamide
por: Wassner, Chanie, et al.
Publicado: (2020)

Urine Assay to Measure Tenofovir Concentrations in Patients Taking Tenofovir Alafenamide
por: Lalley-Chareczko, Linden, et al.
Publicado: (2020)

Converting from Tenofovir Disoproxil Fumarate to Tenofovir Alafenamide in Patients with Hepatitis B Following Liver Transplantation
por: Cheng, Chih-Hsien, et al.
Publicado: (2023)

Population pharmacokinetics of tenofovir given as either tenofovir disoproxil fumarate or tenofovir alafenamide in an African population
por: Kawuma, Aida N., et al.
Publicado: (2023)

Renal safety of tenofovir alafenamide vs. tenofovir disoproxil fumarate: a pooled analysis of 26 clinical trials
por: Gupta, Samir K., et al.
Publicado: (2019)

Equivalent Decline in Inflammation Markers with Tenofovir Disoproxil Fumarate vs. Tenofovir Alafenamide
por: Funderburg, Nicholas T., et al.
Publicado: (2016)

Real-world impact of switching from tenofovir disoproxil fumarate to tenofovir alafenamide
por: Michienzi, Sarah M, et al.
Publicado: (2021)

Tenofovir alafenamide and tenofovir disoproxil fumarate reduce incidence of hepatocellular carcinoma in patients with chronic hepatitis B
por: Lim, Young-Suk, et al.
Publicado: (2023)

Real-life safety of Emtricitabine/Tenofovir Alafenamide/Bictegravir
por: Squillace, Nicola, et al.
Publicado: (2023)

Meta-Analysis of Efficacy and Safety of Coformulated Bictegravir, Emtricitabine, and Tenofovir Alafenamide Among People Living with HIV
por: Chen, I-Wen, et al.
Publicado: (2021)

Dyslipidemia in chronic hepatitis B patients on tenofovir alafenamide: Facts and puzzles
por: Lin, Hung-Yao, et al.
Publicado: (2022)

Tenofovir alafenamide versus tenofovir disoproxil fumarate: is there a true difference in efficacy and safety?
por: Hill, Andrew, et al.
Publicado: (2018)

Atherosclerotic Cardiovascular Disease Risk Profile of Tenofovir Alafenamide Versus Tenofovir Disoproxil Fumarate
por: Huhn, Gregory D, et al.
Publicado: (2019)

Adherence Predictors in Pregnant Women Living with HIV on Tenofovir Alafenamide and Tenofovir Disoproxil Fumarate
por: Eke, Ahizechukwu C
Publicado: (2022)

Distribution Evaluation of Tenofovir in the Breast Milk of Mothers With HBeAg-Positive Chronic HBV Infection After Treatment With Tenofovir Alafenamide and Tenofovir Disoproxil Fumarate by a Sensitive UPLC-MS/MS Method
por: Yang, Na, et al.
Publicado: (2021)

Estimated changes in price discounts for tenofovir-inclusive HIV treatments following introduction of tenofovir alafenamide
por: Dickson, Sean, et al.
Publicado: (2022)

The effect of depot medroxyprogesterone acetate on tenofovir alafenamide in rhesus macaques
por: Daly, Michele B., et al.
Publicado: (2020)

Tenofovir alafenamide nephrotoxicity: a case report and literature review
por: Ueaphongsukkit, Thornthun, et al.
Publicado: (2021)

Effects of Genetic Polymorphisms of Cathepsin A on Metabolism of Tenofovir Alafenamide
por: Ito, Soichiro, et al.
Publicado: (2021)

Real-Life Experience With Bictegravir/Emtricitabine/Tenofovir Alafenamide in Turkey
por: Balcı, Umay, et al.
Publicado: (2023)

One-year efficacy of tenofovir alafenamide in patients with chronic hepatitis B: An observational study
por: Chen, Yi-Cheng, et al.
Publicado: (2022)

Pharmacokinetics of Tenofovir Alafenamide Fumarate and Tenofovir in the Chinese People: Effects of Non-Genetic Factors and Genetic Variations
por: Li, Xue, et al.
Publicado: (2021)

Effect of switching from tenofovir disoproxil fumarate to tenofovir alafenamide on lipid profiles in patients with hepatitis B
por: Suzuki, Kazuharu, et al.
Publicado: (2022)

Pregnancy Outcomes in Pregnant Women with HIV on Tenofovir Disoproxil Fumarate (TDF) Compared to Tenofovir Alafenamide (TAF)
por: Thimm, Matthew A., et al.
Publicado: (2022)

Prescribing rates and characteristics of recipients of tenofovir-containing regimens before and after market entry of tenofovir alafenamide
por: Hung, Anna, et al.
Publicado: (2020)

Pre-Clinical Evaluation of Tenofovir and Tenofovir Alafenamide for HIV-1 Pre-Exposure Prophylaxis in Foreskin Tissue
por: Else, Laura, et al.
Publicado: (2022)

Chronic Hepatitis B Relapse Rates after Cessation of Tenofovir Alafenamide and Entecavir Therapy
por: Huang, Chih-Wen, et al.
Publicado: (2023)

Renal function change after switching tenofovir disoproxil fumarate for tenofovir alafenamide in the HIV-positive patients of a metropolitan sexual health service
por: Turner, Dane, et al.
Publicado: (2019)

Renal proximal tubulopathy in an HIV-infected patient treated with tenofovir alafenamide and gentamicin: a case report
por: Heron, Jack E., et al.
Publicado: (2020)

Bictegravir/Emtricitabine/Tenofovir Alafenamide: A Review in HIV-1 Infection
por: Deeks, Emma D.
Publicado: (2018)

Tenofovir alafenamide nephrotoxicity in an HIV-positive patient: A case report
por: Novick, Tessa K., et al.
Publicado: (2017)

Alopecia After Switch to Tenofovir Alafenamide in 6 African American Women
por: El Zein, Said, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_sdq9thff0b3rln65c699jd43qj